Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

OnKure Therapeutics, Inc.

OKUR · Nasdaq · CIK 0001637715 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

4 Form 4 transaction lines observed in the same window
4 sales · 0 option, withholding, award, gift or other lines

Last qualifying purchase2025-05-15 · ACORN BIOVENTURES, L.P.; ACORN CAPITAL ADVISORS GP, LLC; Hove Anders D · $2.6M

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Saccomano Nicholas APresident and CEO
▼▼
Leverone Jason A.Chief Financial Officer
▼▼
● Purchase▼ Sale○ Other

—

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-05-15 · ACORN BIOVENTURES, L.P.; ACORN CAPITAL ADVISORS GP, LLC; Hove Anders D.

Recent Form 4 activity

0Purchases
8Sales
2Other Form 4 lines
10SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING4 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
1,223,923
Previous report
1,375,252
Avg daily volume
257,074
Days to cover
4.8

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2025-05-15ACORN BIOVENTURES, L.P.; ACORN CAPITAL ADVISORS GP, LLC; Hove Anders DPurchase (P)Common Stock1,400,000USD 1.85USD 2,590,000SEC filing ↗
2024-09-25Leonard Braden MichaelPurchase (P)Common Stock68,746USD 1.50USD 103,119SEC filing ↗
2024-09-24Leonard Braden MichaelPurchase (P)Common Stock29,600USD 1.41USD 41,736SEC filing ↗
2024-09-18Leonard Braden MichaelPurchase (P)Common Stock806USD 1.40USD 1,128SEC filing ↗
2024-09-17Leonard Braden MichaelPurchase (P)Common Stock55,300USD 1.36USD 75,208SEC filing ↗
2024-09-16Leonard Braden MichaelPurchase (P)Common Stock172,747USD 1.37USD 236,663SEC filing ↗
2024-09-13Leonard Braden MichaelPurchase (P)Common Stock150,000USD 1.31USD 196,500SEC filing ↗
2024-09-12Leonard Braden MichaelPurchase (P)Common Stock36,176USD 1.40USD 50,646SEC filing ↗
2024-08-14Leonard Braden MichaelPurchase (P)Common Stock100,487USD 1.41USD 141,687SEC filing ↗
2024-08-13Leonard Braden MichaelPurchase (P)Common Stock171,339USD 1.39USD 238,161SEC filing ↗
2024-05-14Leonard Braden MichaelPurchase (P)Common Stock414,281USD 1.54USD 639,578SEC filing ↗
2023-05-08O'Donnell NiallPurchase (P)Common Stock125,000USD 8.00USD 1,000,000SEC filing ↗
2022-09-01Cruse MichaelPurchase (P)Common Stock7,500USD 3.39USD 25,425SEC filing ↗
2022-08-31Cruse MichaelPurchase (P)Common Stock3,212USD 3.21USD 10,311SEC filing ↗
2022-08-30Cruse MichaelPurchase (P)Common Stock2,820USD 3.18USD 8,967SEC filing ↗

Form 4 evidence

10 transaction lines in the latest 365-day window; 92 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-21Saccomano Nicholas ASale (S)Class A Common Stock87USD 2.97USD 258SEC filing ↗
2026-09-21Leverone Jason A.Sale (S)Class A Common Stock302USD 2.97USD 897SEC filing ↗
2026-06-22Saccomano Nicholas ASale (S)Class A Common Stock86USD 4.40USD 378SEC filing ↗
Show recent Form 4 evidence (10 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-21Saccomano Nicholas ASale (S)Class A Common Stock87USD 2.97USD 258SEC filing ↗
2026-09-21Leverone Jason A.Sale (S)Class A Common Stock302USD 2.97USD 897SEC filing ↗
2026-06-22Saccomano Nicholas ASale (S)Class A Common Stock86USD 4.40USD 378SEC filing ↗
2026-06-22Leverone Jason A.Sale (S)Class A Common Stock303USD 4.40USD 1,333SEC filing ↗
2026-03-23Saccomano Nicholas ASale (S)Class A Common Stock86USD 4.16USD 358SEC filing ↗
2026-03-23Leverone Jason A.Sale (S)Class A Common Stock301USD 4.16USD 1,252SEC filing ↗
2025-12-31Mathers Edward TAward / grant (A)Class A Common Stock3,911USD 0.00USD 0SEC filing ↗
2025-12-31Manke IsaacAward / grant (A)Class A Common Stock5,258USD 0.00USD 0SEC filing ↗
2025-12-22Saccomano Nicholas ASale (S)Class A Common Stock87USD 2.97USD 258SEC filing ↗
2025-12-22Leverone Jason A.Sale (S)Class A Common Stock302USD 2.97USD 897SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerOKUR
CIK0001637715
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history92 transaction lines from 2021-04-09 to 2026-09-21
38 P purchase lines · 21 S sale lines · 33 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.